Not applicableUnknownNCT04116086What this trial is testingUsing PSMA PET-CT as a Diagnostic Tool for Detection of Prostatic Cancer at an Early StageWho this might be right forProstate Cancer Sheba Medical Center 50
Early research (Phase 1)Ended earlyNCT03619655What this trial is testingAssessment of Multi-Modality Quantitative Imaging for Evaluation of Response of Metastatic Prostate Cancer to TherapyWho this might be right forProstate Cancer Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 3
Large-scale testing (Phase 3)Looking for participantsNCT06565247What this trial is testingEvaluation of PSMA-PET and mpMRI in High-risk Prostate Cancer - Using Histopathologic ValidationWho this might be right forProstate Cancer Region Västerbotten 60
Not applicableStudy completedNCT05022576What this trial is testingRobotic-arm Assisted Ga-68 PSMA PET/CT Guided Transgluteal Prostate BiopsyWho this might be right forProstate Cancer Post Graduate Institute of Medical Education and Research, Chandigarh 78
Not applicableLooking for participantsNCT05644080What this trial is testing68Ga/177Lu-PSMA Theranostics in Recurrent Grade 3 and Grade 4 GliomaWho this might be right forHigh Grade Glioma St. Olavs Hospital 10
Early research (Phase 1)Temporarily pausedNCT00664196What this trial is testingTrial of Anti-PSMA Designer T Cells in Advanced Prostate Cancer After Non-Myeloablative ConditioningWho this might be right forProstate Cancer Roger Williams Medical Center 18
Not applicableLooking for participantsNCT07184970What this trial is testingPRISM Study: Prostate Recurrence Detection Using Imaging With PSMA PET/MRI Post-high Intensity Focused UltrasoundWho this might be right forProstate Cancer NYU Langone Health 60
Testing effectiveness (Phase 2)Study completedNCT02607553What this trial is testingSafety and Activity of G-202 in Patients With Clear Cell Renal Cell Carcinoma That Expresses PSMAWho this might be right forClear Cell Renal Cell Carcinoma GenSpera, Inc. 2
Testing effectiveness (Phase 2)Looking for participantsNCT06904313What this trial is testingUltralow Dose PET Imaging for PSMA ExpressionWho this might be right forHealthy VolunteerProstate CA Akiva Mintz 200
Not applicableLooking for participantsNCT06859203What this trial is testingA Prospective, Bicentric Evaluation of Fluciclovine PET-imaging in Patients with Prior Negative or Inconclusive PSMA-ligand PETWho this might be right forBiochemical Recurrence of Malignant Neoplasm of Prostate Technical University of Munich 94
Testing effectiveness (Phase 2)Study completedNCT02488070What this trial is testing68Ga-PSMA PET/CT or PET/MRI in Evaluating Patients With Recurrent Prostate CancerWho this might be right forRecurrent Prostate Carcinoma Stanford University 10
Not applicableLooking for participantsNCT06209853What this trial is testingCorrelation Between PSA Levels and F-18 PSMA PET/CT Findings in Prostate Cancer PatientWho this might be right forProstatic Neoplasms Assiut University 59
Not applicableUnknownNCT03507595What this trial is testingEvaluation of the Metastasis and Recurrence of Prostate CancerWho this might be right forProstate Cancer (Diagnosis)Prostate Cancer MetastaticProstate Cancer Recurrent+1 more Xinhua Hospital, Shanghai Jiao Tong University School of Medicine 400
Not applicableWithdrawnNCT04742972What this trial is testingProstate PMSABR StudyWho this might be right forProstate Cancer Darren Poon
Not applicableLooking for participantsNCT03327675What this trial is testingHigh Precision Imaging of Prostate Specific Membrane Antigen for Personalized Treatment in Prostate CancerWho this might be right forProstate Cancer Universitaire Ziekenhuizen KU Leuven 188
Testing effectiveness (Phase 2)Looking for participantsNCT06970119What this trial is testingA Multicenter, Open-label, Non-randomized Phase I/IIa Clinical Trial to Evaluate INR102 Injection in Patients With Prostate CancerWho this might be right forProstate Cancer Yunhe Pharmaceutical (Tianjin) Co., Ltd 55
Not applicableLooking for participantsNCT06600802What this trial is testingIntrinsic Validity of Molecular Marker(s) Detection on Tissular Tumoral DNA to Predict the Efficacy of 177Lutetium-PSMA-617 (Lu-PSMA) Treatment for Castration-resistant Metastatic Prostate CancerWho this might be right forCastration-resistant Metastatic Prostate CancerTreated by 177Lutetium-PSMA-617 (Lu-PSMA) Centre Jean Perrin 120
Early research (Phase 1)Looking for participantsNCT05656573What this trial is testingCART-PSMA Cells for Advanced Prostate CancerWho this might be right forProstate Cancer Nova Therapeutics LLC 20
Early research (Phase 1)Looking for participantsNCT04167969What this trial is testingThe Use of Nanoparticles to Guide the Surgical Treatment of Prostate CancerWho this might be right forProstate Cancer Memorial Sloan Kettering Cancer Center 16
Testing effectiveness (Phase 2)Looking for participantsNCT06526299What this trial is testingLow PSMA SUV Boost (LPS-Boost): Intensified 177Lu-PSMA-617 Treatment for Patients With Metastatic Castrate-Resistant Prostate Cancer With Low PSMA Expressing DiseaseWho this might be right forMetastatic Castration-Resistant Prostate CarcinomaStage IVB Prostate Cancer AJCC v8 University of Washington 51